The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

hepatitis C

Gilead pushes hep C testing in baby boomers as its blockbusters plummet

Value investors pile into Gilead expecting strong long-term growth: report